Severe human adenovirus (HAdV) infections are an increasing threat for immunosuppressed individuals, particularly those who have received stem cell transplants. It has been previously hypothesized that severe infections might be due to reactivation of a persistent infection, but this hypothesis has been difficult to test owing to the lack of a permissive in vivo model of HAdV infection. Here we established a humanized mouse model that reproduces features of acute and persistent HAdV infection. In this model, acute infection correlated with high mortality, weight loss, liver pathology, and expression of viral proteins in several organs. In contrast, persistent infection was asymptomatic and led to establishment of HAdV-specific adaptive immunity and expression of early viral genes exclusively in the bone marrow. These findings validate the use of humanized mice to study acute and persistent HAdV infection and strongly suggest the presence of cellular reservoirs in the bone marrow.

Human adenoviruses (HAdVs) cause asymptomatic-to-mild respiratory infections in children and young adults [1]. Some species also cause infections of the gastrointestinal tract and the conjunctiva. However, in immunocompromised patients, HAdV may cause severe symptoms, such as hepatitis, nephritis, meningoencephalitis, and pneumonia. This is especially problematic in patients undergoing transplantation [2, 3]. In these patients, it is thought that HAdV infections arise from the reactivation of a persistent/latent infection in the donor bone marrow and/or in the recipient [4]. However, this hypothesis has not been experimentally addressed. Presently, no specific treatments exist against severe HAdV infections, which may have mortality rates of up to 70%, especially in pediatric patients undergoing stem cell transplantation [5].

Several studies have found HAdV DNA, mainly of species C origin, in tonsils, adenoids, and mucosal lymphocytes [69] long after recovery from infection. HAdV DNA has also been detected in tumors [1012], mainly within tumor-infiltrated lymphoid cells [11]. In addition, persistent HAdV infections have been established in blood-derived cell lines [1316]. These data point to hematopoietic cells as a putative reservoir for HAdV. To date, the mechanisms that control persistent infection in vivo and the specific cell reservoir remain unknown. This is in part due to the lack of small-animal models to study HAdV persistence in vivo. Animal models have been difficult to establish because of the species-specificity of adenoviruses. HAdV can only infect human cells, and classical mouse models are not permissive for HAdV infection.

In recent years, the establishment of humanized mice harboring human hematopoietic cells has rapidly developed, and such models have proven to be useful for the study of several human diseases. However, only a few studies have utilized humanized mice to investigate human viral infections [1721], including Epstein-Barr virus, dengue virus, human immunodeficiency virus (HIV), and, very recently, Ebola virus [2226]. Owing to the species-specificity of HAdVs and the long-lasting human engraftment in these mice [27], we reasoned that they may constitute a potential model for studying the pathogenesis of acute and persistent HAdV infection [22].

Here we present a humanized mouse model for HAdV that can reproduce both acute/severe and persistent/latent HAdV infections. We have observed that 34% of HAdV-infected humanized NSG (huNSG) mice developed liver pathology leading to viral hepatitis and HAdV disease dissemination, consistent with acute HAdV infection. Conversely, 66% of the animals remained asymptomatic and developed antigen-specific T-cell responses. These mice harbored HAdV persistent infection in bone marrow and peripheral blood cells. Our model constitutes a novel in vivo system to study the pathophysiology of HAdV infections in a human context and may be a useful tool to investigate mechanisms of persistence and virus reactivation.

METHODS

Generation of Humanized Mice and Detection of Human Engraftment

Humanized mice were generated as previously described [26] (Figure 1A). Briefly, 4–5-week-old female NOD.Cg-PrkdcscidIl2rgtm1WjlTg(HLA-A2.1)1Enge/SzJ (NSG-A2) mice (Jackson Laboratories) were conditioned by sublethal irradiation (240 cGy) and then underwent intravenous (retro-orbital) transplantation with 106 HLA-A2–matching CD34+ human hematopoietic stem and progenitor cells (HSPCs) per mouse. Human HSPCs were isolated from cord blood after receipt of informed written consent and in accordance with protocols for anonymized sample collection that were approved by the local ethics committee (Ethik-Kommission der Ärztekammer Hamburg, Germany). Animal experiments were performed under protocols approved by the German animal protection authorities (Behörde für Gesundheit und Verbraucherschutz, Hamburg, Germany [protocol 69/13]).
Morbidity and mortality due to human adenovirus (HAdV) in humanized NSG-A2 mice. A, Diagram showing the protocol followed to generate the NSG-A2 humanized mice. B, Kaplan–Meier survival curve of mice with high human chimerism (defined as mice in which >30% of peripheral blood cells were hCD45+ cells). Mice were infected with either 104 or 108 fluorescence-forming units (ffu)/mouse or were mock infected (with phosphate-buffered saline). C, The percentage of mice with acute (black) or asymptomatic (gray) infection. The upper chart shows the total disease distribution. The lower charts show the disease distribution by human engraftment in peripheral blood, with high engraftments defined as a peripheral blood cell population in which >30% of cells were hCD45+, medium engraftment defined as one in which 30%–15% were hCD45+, and low engraftment defined as one in which <15% were hCD45+). Disease distribution was calculated as the percentage of mice that developed an acute or asymptomatic infection per group. The total number of animals per group is shown in parentheses. D, Graph showing weight loss of acute and asymptomatic mice with high human engraftment, depicted as the percentage of initial weight. Mean values and standard errors of the mean are represented. A total of 30 mice were used for this analysis (6 were mock infected, 11 were infected with 104 ffu/mouse, and 13 were infected with 108 ffu/mouse).
Figure 1.

Morbidity and mortality due to human adenovirus (HAdV) in humanized NSG-A2 mice. A, Diagram showing the protocol followed to generate the NSG-A2 humanized mice. B, Kaplan–Meier survival curve of mice with high human chimerism (defined as mice in which >30% of peripheral blood cells were hCD45+ cells). Mice were infected with either 104 or 108 fluorescence-forming units (ffu)/mouse or were mock infected (with phosphate-buffered saline). C, The percentage of mice with acute (black) or asymptomatic (gray) infection. The upper chart shows the total disease distribution. The lower charts show the disease distribution by human engraftment in peripheral blood, with high engraftments defined as a peripheral blood cell population in which >30% of cells were hCD45+, medium engraftment defined as one in which 30%–15% were hCD45+, and low engraftment defined as one in which <15% were hCD45+). Disease distribution was calculated as the percentage of mice that developed an acute or asymptomatic infection per group. The total number of animals per group is shown in parentheses. D, Graph showing weight loss of acute and asymptomatic mice with high human engraftment, depicted as the percentage of initial weight. Mean values and standard errors of the mean are represented. A total of 30 mice were used for this analysis (6 were mock infected, 11 were infected with 104 ffu/mouse, and 13 were infected with 108 ffu/mouse).

Eight weeks after HSPC transplantation, blood samples were collected from animals, and human chimerism was quantified by flow cytometry after red blood cell depletion (RBC Lysis Buffer; Biolegend) and staining with anti-human CD45 antibody (clone HI30; Biolegend). Samples were analyzed in a FACS Canto II flow cytometer (BD Bioscience). For data analysis, animals were classified into 3 groups on the basis of the level of human engraftment, with the high-engraftment group comprising animals in which >30% of peripheral blood cells were human hematopoietic cells (hCD45+), the medium-engraftment group comprising those in which the hCD45+ cell proportion was 15%–30%, and the low-engraftment group comprising those in which the hCD45+ cell proportion was <15%.

Virus Production, Infections, and Disease Monitoring

Wild-type HAdV serotype 2 (HAdV2) from species C (ATCC) was produced in either A549 or HEK293 cells and was purified with CsCl. Amicon Ultra columns (Ultracel-100K, Millipore) were used for buffer exchange (with phosphate-buffered saline [PBS]) and to obtain a high concentrated stock. Virus stocks were titered in the same cell lines by immunofluorescence against the E2A protein as previously described [28].

On week 9 after transplantation, mice were intravenously infected with 104 or 108 fluorescence-forming units per mouse of HAdV2 or were mock infected (with 1× PBS intravenously). Weight loss and signs of disease (lethargy and ruffled fur) were monitored daily. Animals that lost >25% of their initial body weight were euthanized. Asymptomatic mice were euthanized 2 months after infection. At the time of death, different organs/tissues were harvested and either snap frozen in liquid nitrogen and stored at −80°C or fixed for histologic preparation.

RNA Extraction and Reverse-Transcription Polymerase Chain Reaction (RT-PCR)

TRIzol (ThermoFisher Scientific)/chloroform extraction was used to obtained RNA from frozen tissue, followed by DNase treatment (Qiagen) and purification using the RNeasy mini kit (Qiagen). RNA extraction of peripheral blood mononuclear cells and bone marrow cells was done by cell lysis in RLTplus buffer (Qiagen) and using the RNeasy Mini kit (Qiagen). One microgram of total RNA was reversed transcribed by using the Reverse Transcription System and random primers (Promega). PCR was performed in the RotorGene Q cycler (Qiagen), using the SensiMix SYBR-Hi-ROX (Bioline). All values were normalized to GAPDH levels. Samples were run in duplicates. Primers for genes encoding E1A, hexon, and GAPDH have been previously described [11].

Histopathologic and Immunohistochemical (IHC) Analyses

Organs were fixed in formalin (ProTaqs 4% formaldehyde; Quartett) and then embedded in paraffin. Bones were first immersed in Calfix solution (Protaqs, Quartett) and decalcified (Protaqs Calless, Quartett). Sections were cut (thickness, 4 µm) and stained with hematoxylin-eosin. For analysis of fibrosis, samples were stained with Picro Sirius Red solution (Sirius red dye in picric acid) according to standard procedures. For the detection of specific proteins, antigen retrieval was performed by boiling deparaffinized sections for 30–60 minutes in 10 mM citrate buffer (pH 6.0). For monocyte/macrophage detection, samples were incubated with Iba1 antibody (1:1500; Wako Chemicals). To stain proliferating cells, samples were incubated with Ki67 antibody (dilution, 1:1000; Sigma Aldrich). The following antibodies were used to stain adenoviral proteins: E1A monoclonal antibody (M73; dilution, 1:3) [29], E2A-72K monoclonal antibody (B6-8; dilution, 1:3) [30], and HAdV5 RbAb (L133; dilution, 1:400) [31]. For detection of specific binding, the Ultra View Universal DAB Detection Kit (Ventana, Roche) was used.

Analysis of HAdV-Specific T-Cell Responses

Splenocytes were resuspended in Roswell Park Memorial Institute medium containing 25 µg of HAdV2 (inactivated at 60°C for 30 minutes), 1 µg of purified mouse anti-human CD28 (BD Bioscience), brefeldin A (dilution, 1:1000; BD GolgiPlug; BD Bioscience), and Fc receptor–blocking solution (dilution, 1:100; Human TruStain FcX; Biolegend). A positive control for nonspecific T-cell activation was included by resuspending an aliquot of splenocytes in Roswell Park Memorial Institute medium, 1:1000 BD GolgiPlug, 1:100 Human TruStain FcX, 20 ng/mL PMA, and 1 µg/mL ionomycin. All samples were incubated overnight at 37°C. Cells were stained on the following day with different antibodies to detect interferon γ (IFN-γ) production in CD8+ T cells by flow cytometry (FACS Canto II, BD Bioscience). Data were analyzed with FlowJo software (TreeStar).

Enzyme-Linked Immunosorbent Assay (ELISA) to Detect HAdV-Specific Antibodies

ELISA plates were coated with heat-inactivated HAdV2 particles overnight, as described elsewhere [32]. On the next day, plates were blocked with 20% fetal bovine serum (FBS) and then incubated with each serum (1:20 dilution in PBS plus 10% FBS) for 2 hours at room temperature. Plates were washed with PBS-Tween 0.05% and incubated for 1 hour at room temperature with 1:1000 dilution of mouse anti-human immunoglobulin M (IgM)–horseradish peroxidase (Southern Biotech). HAdV-specific antibodies were detected by incubation with tetramethylbenzidine substrate (Biolegend) and absorbance reading at 450 nm. For background measurement, absorbance at 570 nm was subtracted from the value at 450 nm. Measurements were done in duplicate. The assay was validated by a standard curve of serial dilutions of HAdV-positive serum. A titration curve for the coating antigen was performed; the detection limit was estimated in 1.12 ng/µL of inactivated antigen. Plates were coated with 700 ng/µL of inactivated antigen. The threshold to consider samples positive was calculated as the average of mock values plus 1 SD.

Statistical Analysis

For statistical analysis, the Kruskal–Wallis Test was used, followed by the Dunn multiple comparison post hoc test. Analysis was done in Prism 5 (GraphPad).

RESULTS

HAdV Causes Disease in huNSG Mice

To generate humanized mice, we used NSG transgenic mice expressing human HLA-A2.1 (NSG-A2), in which the immune system was reconstituted with cord blood–isolated HSPCs (Figure 1A and Supplementary Figures 1 and 2). Nine weeks after transplantation, animals were infected with 104 or 108 fluorescence-forming units of HAdV2 per mouse. We first analyzed the overall morbidity and mortality by measuring survival, changes in body weight, and disease development. Thirty-four percent of infected mice (14 of 41) developed signs of disease, such as lethargy, ruffled fur, and progressive weight loss, and died of infection between day 6 and day 26 after infection, while 66% (27 of 41) remained asymptomatic (Figure 1C). We reasoned that these differences could be due to variations in the degree of human chimerism. In agreement with this hypothesis, we observed that highly engrafted mice had significant weight loss and decreased survival when infected with either dose of HAdV2 (Figure 1B and 1D). Highly engrafted mock-infected mice (Figure 1B and 1D), as well as nonhumanized mice (Supplementary Figure 3), remained asymptomatic, indicating that morbidity was associated with HAdV infection and not with hematopoietic chimerism. HAdV-infected mice with medium and those with low engraftment did not show significant weight loss or decreased survival as compared to mock animals (Supplementary Figure 4). These results strongly suggest that the ability of HAdV to cause disease in our model depends on the availability of target human cells, strengthening the idea that our system mimics in vivo HAdV infection in a human context.

Acutely Infected Mice Developed Viral Hepatitis due to HAdV2 Replication

We observed 2 outcome populations: asymptomatic animals and animals that developed signs of disseminated HAdV disease. Animals with suspected disseminated disease presented with macroscopic features of liver pathology, including pale yellow appearance, light spots, hemorrhage, and uneven edges (data not shown). To better characterize this phenotype, livers sections were examined using specific staining for fibrosis, proliferation, and infiltration of immune cells, as well as virus-specific antibodies. Livers from mice with acute infection had severe intrahepatocellular vacuolization (Figure 2A), increased monocyte/macrophage infiltration and activation, increased cell proliferation, and liver fibrosis (Figure 2B). This phenotype was mainly observed in highly engrafted mice infected with 108 fluorescence-forming units of HAdV2. Conversely, humanized asymptomatic infected mice and infected mice that did not undergo transplantation did not show pathological signs (Figure 2). Interestingly, HAdV could be rescued from liver homogenates and serum of 2 severely sick mice after 2 passages on A549 cells, indicating the development of disseminated disease due to HAdV in these animals.
Liver pathology analysis in mice with acute human adenovirus (HAdV) infection. Representative micrographs of liver sections from HAdV2-infected and mock-infected humanized NSG-A2 mice, stained with hematoxylin-eosin (A) and Picro Sirius Red (B), which was used to stain collagen in damaged livers, highlighting fibrotic tissue; IBA1 antibody, which was use to stain monocytes/macrophages; and Ki67 antibody, which was used to mark proliferating cells. Arrowheads indicate cells lacking a nucleus. Arrows highlight vacuolization in hepatocytes. Scale bar represents 0.5 µm in all magnifications.
Figure 2.

Liver pathology analysis in mice with acute human adenovirus (HAdV) infection. Representative micrographs of liver sections from HAdV2-infected and mock-infected humanized NSG-A2 mice, stained with hematoxylin-eosin (A) and Picro Sirius Red (B), which was used to stain collagen in damaged livers, highlighting fibrotic tissue; IBA1 antibody, which was use to stain monocytes/macrophages; and Ki67 antibody, which was used to mark proliferating cells. Arrowheads indicate cells lacking a nucleus. Arrows highlight vacuolization in hepatocytes. Scale bar represents 0.5 µm in all magnifications.

Adenovirus Gene and Protein Expression Differentiates Acute From Persistent Infection

E1A is the first viral gene expressed upon infection. It has transcriptional regulatory functions in both viral and cellular promoters. In contrast, hexon is expressed from the major late promoter in the late phase of infection. It encodes a structural protein that forms part of the virion capsid serving as readout of productive/lytic infection [1]. Several reports have indicated that, during persistent HAdV infection, only E1A expression is observed, with very low or no detectable expression of hexon [13, 16, 33]. To understand which type of infection was taking place in HAdV-infected huNSG mice, we investigated the levels of E1A and hexon in both infected and noninfected animals. RT-PCR was used to detect the expression of E1A and hexon genes in different tissues, such as liver, spleen, inguinal lymph nodes, thymus, bone marrow, and peripheral blood. Mice that developed acute HAdV infection showed high levels of both E1A and hexon expression in different tissues (Figure 3A). Interestingly, while messenger RNA (mRNA) levels were higher in bone marrow than in liver samples, opposite results were observed in the same tissues with regard to the number of viral genome copies (Supplementary Figure 5), suggesting that the transcriptional activity of early viral genes in the bone marrow is higher than in the liver. In addition, E1A, E2A, and capsid proteins were detected by IHC analysis in the liver of huNSG mice with acute infection (Figure 4AD), indicating that an active infection had been established in the liver of these animals, causing HAdV-induced hepatitis. However, viral proteins were not detectable in other HAdV mRNA–positive tissues, such as bone marrow (Figure 4E and 4F), suggesting a persistent infection in this tissue.
Detection of human adenovirus (HAdV) messenger RNA (mRNA) in different tissues. Absolute mRNA levels for E1A and hexon expression are shown. A, Graph showing E1A (left panel) and hexon (right panel) expression in mice with acute humanized NSG-A2 infection. B, Graph displays values for the same genes in asymptomatic infected animals. Each dot represents one animal, mean values and standard errors of the mean are shown for each tissue. The number of samples per group is shown in parentheses. The gene encoding GAPDH was used as housekeeping gene to normalize the data. The red dotted line is the threshold for a sample to be positive, and it is calculated on the basis of the mRNA levels for each gene in the mock-infected animals. Abbreviations: BM, bone marrow; LN, lymph node.
Figure 3.

Detection of human adenovirus (HAdV) messenger RNA (mRNA) in different tissues. Absolute mRNA levels for E1A and hexon expression are shown. A, Graph showing E1A (left panel) and hexon (right panel) expression in mice with acute humanized NSG-A2 infection. B, Graph displays values for the same genes in asymptomatic infected animals. Each dot represents one animal, mean values and standard errors of the mean are shown for each tissue. The number of samples per group is shown in parentheses. The gene encoding GAPDH was used as housekeeping gene to normalize the data. The red dotted line is the threshold for a sample to be positive, and it is calculated on the basis of the mRNA levels for each gene in the mock-infected animals. Abbreviations: BM, bone marrow; LN, lymph node.

Detection of human adenovirus (HAdV) proteins in liver and bone marrow. E1A, E2A, and capsid proteins in formalin-fixed, paraffin-embedded tissue samples underwent immunohistochemical analysis. A–D, Representative micrographs of liver sections from mice with acute infection, showing results of E1A staining (A and B), capsid staining (C), and E2A staining (D). E–G, Representative micrographs of bone marrow sections stained with E2A antibody, showing results for mock-infected mice (E), mice with acute infection (F), and mice with asymptomatic infection (G). Arrows point to cells that stained positive for each antibody. The scale bar is 0.5 µm. All pictures were taken at 20 times the original magnification.
Figure 4.

Detection of human adenovirus (HAdV) proteins in liver and bone marrow. E1A, E2A, and capsid proteins in formalin-fixed, paraffin-embedded tissue samples underwent immunohistochemical analysis. AD, Representative micrographs of liver sections from mice with acute infection, showing results of E1A staining (A and B), capsid staining (C), and E2A staining (D). EG, Representative micrographs of bone marrow sections stained with E2A antibody, showing results for mock-infected mice (E), mice with acute infection (F), and mice with asymptomatic infection (G). Arrows point to cells that stained positive for each antibody. The scale bar is 0.5 µm. All pictures were taken at 20 times the original magnification.

To investigate whether HAdV gene expression could still be found in asymptomatic-infected mice 2 months after infection, we performed RT-PCR to detect E1A and hexon expression in the same tissues. In these animals, only E1A expression but low or no hexon expression could be detected in the bone marrow and peripheral blood (Figure 3B). Similar to what we have observed in the bone marrow of acutely infected mice, no viral proteins were detected by IHC in the bone marrow of HAdV-infected asymptomatic animals (Figure 4G). These results indicate that HAdV might be causing a persistent infection in the bone marrow of HAdV humanized mice with acute or asymptomatic infection.

Adaptive Immune Responses Mark Acute Versus Persistent Infection

The adaptive immune response to HAdV involves both antibody and cellular immunity [34]. We could detect a significant increase in IgM production in mice with acute infection, compared with mock-infected mice (P < .005) and asymptomatic mice (P < .05; Figure 5A). In addition, asymptomatic mice were able to generate HAdV-specific CD8+ T cells, as measured by the production of IFN-γ after specific T-cell restimulation. The amount IFN-γ production was significantly higher (P < .005) in mice infected with 104 fluorescence-forming units of HAdV as compared to production in mock-infected mice (Figure 5B). These results indicate that huNSG mice infected with HAdV can mount adaptive immune responses that can differentiate mice with acute infection from those with persistent infection.
Adaptive immune response to human adenovirus (HAdV) infection in humanized NSG-A2 mice. A, Immunoglobulin M (IgM) levels measured by enzyme-linked immunosorbent assay (ELISA) in the serum of mock-infected mice and those with acute or asymptomatic infection are shown. The red dotted line indicates the threshold for a positive sample and is calculated as the average of the mock values plus 1 standard deviation. The Kruskal–Wallis test was performed for statistical analysis (P = .0021), followed by a Dunn multiple comparison test. *P < .05 for comparisons of the acute infection group to the asymptomatic infection group; **P < .005 for comparison of the mock infection group to the acute infection group. B, The graph shows the percentage of interferon γ (IFN-γ)–expressing CD8+ T cells after specific restimulation of T-cell splenocytes. The Kruskal–Wallis test was performed for statistical analysis (P = .0024), followed by a Dunn multiple comparison test. **P < .005 for comparison of the mock infection group to the group infected with 104 fluorescence-forming units of HAdV. The number of samples per group is shown in parentheses.
Figure 5.

Adaptive immune response to human adenovirus (HAdV) infection in humanized NSG-A2 mice. A, Immunoglobulin M (IgM) levels measured by enzyme-linked immunosorbent assay (ELISA) in the serum of mock-infected mice and those with acute or asymptomatic infection are shown. The red dotted line indicates the threshold for a positive sample and is calculated as the average of the mock values plus 1 standard deviation. The Kruskal–Wallis test was performed for statistical analysis (P = .0021), followed by a Dunn multiple comparison test. *P < .05 for comparisons of the acute infection group to the asymptomatic infection group; **P < .005 for comparison of the mock infection group to the acute infection group. B, The graph shows the percentage of interferon γ (IFN-γ)–expressing CD8+ T cells after specific restimulation of T-cell splenocytes. The Kruskal–Wallis test was performed for statistical analysis (P = .0024), followed by a Dunn multiple comparison test. **P < .005 for comparison of the mock infection group to the group infected with 104 fluorescence-forming units of HAdV. The number of samples per group is shown in parentheses.

DISCUSSION

Adenoviruses cause severe disease in immunocompromised patients, especially in pediatric patients undergoing allogeneic stem cell transplantation [3538]. These patients develop disseminated HAdV disease between 2 and 3 months after transplantation, with the highest incidence ranging from 5% to 47% within the first 100 days after transplantation and with higher mortality rates than infections in adults [5, 34]. Severe HAdV infections in stem cell transplant recipients cause severe manifestations, such as hemorrhagic cystitis, pneumonia, nephritis, encephalitis, myocarditis, and fulminant hepatitis [34, 39]. It is thought that these infections arise from reactivation of latent/persistent HAdV infection, rather than reinfection [38]. Once established, severe HAdV infections are very difficult to cure, and broad-spectrum antiviral drugs are not efficient in most cases, leading to multiorgan failure and death. Owing to the species specificity of adenoviruses, no previous studies have established a permissive mouse model system to study severe HAdV infection, pathology, and treatment. We are the first to present a humanized mouse model, huNSG-A2, that is susceptible to HAdV and shows signs of lytic and persistent infections.

In our study, we have observed that 34% of HAdV-infected humanized mice developed acute/permissive infection. This was correlated with significant weight loss and decreased survival, as well as the onset of liver pathology, including increased hepatocyte vacuolization. These observations resemble the liver phenotype reported in immunosuppressed patients who developed HAdV-induced hepatitis [40]. Similar phenotypes have been observed in studies that tested the biodistribution of replication-deficient adenoviral vectors or the oncolytic effects of replication-competent, cell-targeted vectors, but these studies used viral loads that were 50–1000 times the viral loads we used in the present study [33, 41, 42]. In our model, we used relatively low amounts of a wild-type virus (HAdV type 2), and, in addition to previous observations, we found that humanized mice with acute infection developed liver fibrosis, increased monocyte/macrophage tissue infiltration and activation, and increased cellular proliferation. Moreover, we have observed systemic virus dissemination in 2 mice from which HAdV type 2 could be isolated.

It has been shown by Engler et al that the acute hepatotoxicity observed during HAdV infection is associated with E1A expression, which induces cytokine production (ie, tumor necrosis factor α), causing severe liver inflammation and tissue damage [33]. In line with this, we have observed that huNSG mice with acute infection expressed high levels of E1A in different tissues (liver, bone marrow, lymph nodes, and peripheral blood). Some of these body sites were also positive for transcripts of the late gene hexon, which encodes a major capsid protein. Moreover, we found cells positive for E1A, E2A, and capsid proteins in liver sections from the same animals. These results suggest that, at least in part, E1A expression could be responsible for the development of HAdV-induced hepatitis. Even though previous studies have suggested that HAdV may produce abortive infections in mouse cells [4345], our results show an active/lytic replication of HAdV in huNSG mice. This is supported by the detection of viral proteins in liver tissue and the rescue of viral particles ex vivo, together with increased hCD45+ cell infiltration in the liver of mice with acute infection (unpublished observation). Whether virus replication occurred in hepatocytes or in tissue-infiltrated human blood cells in our specific experimental setup remains unknown and is the aim of current investigations. Interestingly, the lymph nodes of mice with acute infection that were positive for E1A expression did not show any hexon expression, which would suggest that an abortive infection occurred in this lymphoid tissue.

HAdV-positive samples have been found in tonsil and adenoids [6, 8], lymphocytes of the human mucosa, and the gastrointestinal tract long after an acute or asymptomatic infection [7, 9, 46]. In most cases, the presence of HAdV-positive samples was analyzed by detection of E1A and/or hexon DNA sequences. Moreover, some groups could isolate infectious virus from human specimens [6], while others could not [7], suggesting different states of latent/persistent/chronic infection in human subjects. In the last years, several authors have established in vitro systems with blood-derived cell lines to study HAdV persistent infections [13, 16]; however, it remains unclear whether viral gene expression and virus progeny production are characteristics of persistent HAdV infections in vivo.

In our study, the majority (66%) of HAdV-infected humanized mice were asymptomatic, as they did not show any signs of disease or weight loss. During both macroscopic and microscopic analyses, the organs of these animals showed a phenotype similar to that of noninfected (ie, mock-infected) animals. Interestingly, we found few HAdV genome copies in the bone marrow of asymptomatic infected animals, accompanied by high levels of E1A mRNA, 2 months after infection; however, very low or no hexon expression was detected. Our results are in agreement with those of previous studies using cell lines persistently infected with HAdV [13, 16]. Besides, some peripheral blood samples were also positive for E1A mRNA. Although this is a rare event in healthy humans, some studies have found HAdV-positive samples in human peripheral blood donors [47]. Similarly, hepatitis B virus has also been observed to cause persistent infections in peripheral blood lymphocytes and in bone marrow cells, showing also a limited expression of its viral genes [4]. Interestingly, viral proteins could not be detected in the bone marrow of HAdV-infected huNSG mice with acute or asymptomatic infection. These data suggest that within all hematopoietic tissues with human engraftment in our model, a persistent HAdV infection has been established in the bone marrow of these animals. Furthermore, our results suggest that, during persistent infections in vivo, only early viral mRNAs are transcribed, but no viral proteins are produced. This might serve as a mechanism for the virus to evade the immune system and persist. Further experiments to identify the specific cell subpopulation harboring persistent HAdV infection are warranted.

In summary, the differences in viral gene and protein expression in different mouse organs may serve as a tool to differentiate between active/lytic infection, when both early and late genes and proteins are expressed, or persistent/latent infection, when only early but not late genes are expressed or proteins are produced. Accordingly, the immune response to HAdV infection in our model could distinguish between mice with acute and those with persistent infection. Humanized mice that died from the disease showed a significant increase in IgM production as compared to asymptomatic mice. Although this could be due to differences in the timing of sample acquisition, our data suggest that an acute infection was taking place in these animals. On the other hand, and as previously shown for a recombinant HAdV type 5 [48], asymptomatic mice developed HAdV antigen–specific T-cell responses, which surprisingly were significantly higher in mice that were infected using a lower virus load. These could be due to the inhibition of T-cell function caused by excess of antigen (T-cell exhaustion) when using a high viral dose, which is likely to happen because of the HLA-A2–restricted oligoclonal T-cell responses in this model [23, 49, 50]. Further experiments are needed to understand HAdV immune regulation in these animals.

Our humanized mouse model of HAdV infection opens up new opportunities to study HAdV pathology and immune response in vivo. It will permit the investigation of new mechanisms controlling virus persistence and reactivation, and it will contribute to our understanding of the origin of HAdV infections in immunosuppressed patients. Ultimately, our mouse model could be effectively used for the development and validation of new specific antiviral strategies against HAdV infection.

Supplementary Data

Supplementary materials are available at http://jid.oxfordjournals.org. Consisting of data provided by the author to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author.

Notes

Acknowledgments. We thank the animal caretakers from the HPI animal facility, especially Ursula Müller and Ines Jambor, for their daily support of the mouse work; Dr Carol Stoking, for careful revision of the manuscript; and the cord blood donors, nurses, and doctors from the Asklepios Klinik Nord (Hamburg, Germany) who were involved in this project.

Financial support. This work was supported by the Deutsche Forschungsgemeinschaft (grant DO 343/7-1 to T. D.), the Wilhelm Sander-Stiftung (to T. D.), the Freie und Hansestadt Hamburg (to the Heinrich Pette Institute, Leibniz Institute for Experimental Virology), and the Bundesministerium für Gesundheit (to the Heinrich Pette Institute, Leibniz Institute for Experimental Virology).

Potential conflicts of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1

Shenk
T
.
Adenoviridae: the viruses and their replication
. In:
Fields
BN
,
Knipe
DM
,
Howley
PM
, eds.
Virology
. 3rd ed.
Vol 2
.
New York, NY
:
Lippincott-Raven
,
1996
:
2111
48
.

2

Chakrabarti
S
.
Adenovirus infections after hematopoietic stem cell transplantation: still unravelling the story
.
Clin Infect Dis
2007
;
45
:
966
8
.

3

Fowler
CJ
,
Dunlap
J
,
Troyer
D
,
Stenzel
P
,
Epner
E
,
Maziarz
RT
.
Life-threatening adenovirus infections in the setting of the immunocompromised allogeneic stem cell transplant patients
.
Adv Hematol
2010
;
2010
:
601548
.

4

Boldogh
I
,
Albrecht
T
,
Porter
DD
.
Persistent viral infections
. In:
Baron
S
, ed.
Medical microbiology
. 4th ed.
Galveston, TX
,
The University of Texas Medical Branch at Galveston
,
1996
.

5

Sandkovsky
U
,
Vargas
L
,
Florescu
DF
.
Adenovirus: current epidemiology and emerging approaches to prevention and treatment
.
Curr Infect Dis Rep
2014
;
16
:
416
.

6

van der Veen
J
,
Lambriex
M
.
Relationship of adenovirus to lymphocytes in naturally infected human tonsils and adenoids
.
Infect Immun
1973
;
7
:
604
9
.

7

Garnett
CT
,
Erdman
D
,
Xu
W
,
Gooding
LR
.
Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes
.
J Virol
2002
;
76
:
10608
16
.

8

Garnett
CT
,
Talekar
G
,
Mahr
JA
et al. .
Latent species C adenoviruses in human tonsil tissues
.
J Virol
2009
;
83
:
2417
28
.

9

Roy
S
,
Calcedo
R
,
Medina-Jaszek
A
,
Keough
M
,
Peng
H
,
Wilson
JM
.
Adenoviruses in lymphocytes of the human gastro-intestinal tract
.
PLoS One
2011
;
6
:
e24859
.

10

Kosulin
K
,
Haberler
C
,
Hainfellner
JA
,
Amann
G
,
Lang
S
,
Lion
T
.
Investigation of adenovirus occurrence in pediatric tumor entities
.
J Virol
2007
;
81
:
7629
35
.

11

Kosulin
K
,
Hoffmann
F
,
Clauditz
TS
,
Wilczak
W
,
Dobner
T
.
Presence of adenovirus species C in infiltrating lymphocytes of human sarcoma
.
PLoS One
2013
;
8
:
e63646
.

12

Kosulin
K
,
Rauch
M
,
Ambros
PF
et al. .
Screening for adenoviruses in haematological neoplasia: High prevalence in mantle cell lymphoma
.
Eur J Cancer
2014
;
50
:
622
7
.

13

Markel
D
,
Lam
E
,
Harste
G
,
Darr
S
,
Ramke
M
,
Heim
A
.
Type dependent patterns of human adenovirus persistence in human T-lymphocyte cell lines
.
J Med Virol
2014
;
86
:
785
94
.

14

Andiman
WA
,
Miller
G
.
Persistent infection with adenovirus types 5 and 6 in lymphoid cells from humans and woolly monkeys
.
J Infect Dis
1982
;
145
:
83
8
.

15

Chu
Y
,
Sperber
K
,
Mayer
L
,
Hsu
MT
.
Persistent infection of human adenovirus type 5 in human monocyte cell lines
.
Virology
1992
;
188
:
793
800
.

16

Zhang
Y
,
Huang
W
,
Ornelles
DA
,
Gooding
LR
.
Modeling adenovirus latency in human lymphocyte cell lines
.
J Virol
2010
;
84
:
8799
810
.

17

Shultz
LD
,
Ishikawa
F
,
Greiner
DL
.
Humanized mice in translational biomedical research
.
Nat Rev Immunol
2007
;
7
:
118
30
.

18

Pearson
T
,
Greiner
DL
,
Shultz
LD
.
Humanized SCID mouse models for biomedical research
.
Curr Top Microbiol Immunol
2008
;
324
:
25
51
.

19

Brehm
MA
,
Shultz
LD
,
Greiner
DL
.
Humanized mouse models to study human diseases
.
Curr Opin Endocrinol Diabetes Obes
2010
;
17
:
120
5
.

20

Shultz
LD
,
Brehm
MA
,
Bavari
S
,
Greiner
DL
.
Humanized mice as a preclinical tool for infectious disease and biomedical research
.
Ann N Y Acad Sci
2011
;
1245
:
50
4
.

21

Brehm
MA
,
Jouvet
N
,
Greiner
DL
,
Shultz
LD
.
Humanized mice for the study of infectious diseases
.
Curr Opin Immunol
2013
;
25
:
428
35
.

22

Yajima
M
,
Imadome
K
,
Nakagawa
A
et al. .
A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses
.
J Infect Dis
2008
;
198
:
673
82
.

23

Jaiswal
S
,
Pearson
T
,
Friberg
H
et al. .
Dengue virus infection and virus-specific HLA-A2 restricted immune responses in humanized NOD-scid IL2rgammanull mice
.
PLoS One
2009
;
4
:
e7251
.

24

Bente
DA
,
Melkus
MW
,
Garcia
JV
,
Rico-Hesse
R
.
Dengue fever in humanized NOD/SCID mice
.
J Virol
2005
;
79
:
13797
9
.

25

Nischang
M
,
Gers-Huber
G
,
Audige
A
,
Akkina
R
,
Speck
RF
.
Modeling HIV infection and therapies in humanized mice
.
Swiss Med Wkly
2012
;
142
:
w13618
.

26

Ludtke
A
,
Oestereich
L
,
Ruibal
P
et al. .
Ebola virus disease in mice with transplanted human hematopoietic stem cells
.
J Virol
2015
;
89
:
4700
4
.

27

Hiramatsu
H
,
Nishikomori
R
,
Heike
T
et al. .
Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/gammacnull mice model
.
Blood
2003
;
102
:
873
80
.

28

Groitl
P
,
Dobner
T
.
Adenovirus methods and protocols
.
Totowa, NJ
:
Humana
,
2007
.

29

Harlow
E
,
Franza
BR
Jr
,
Schley
C
.
Monoclonal antibodies specific for adenovirus early region 1A proteins: extensive heterogeneity in early region 1A products
.
J Virol
1985
;
55
:
533
46
.

30

Reich
NC
,
Sarnow
P
,
Duprey
E
,
Levine
AJ
.
Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein
.
Virology
1983
;
128
:
480
4
.

31

Kindsmuller
K
,
Groitl
P
,
Hartl
B
,
Blanchette
P
,
Hauber
J
,
Dobner
T
.
Intranuclear targeting and nuclear export of the adenovirus E1B-55K protein are regulated by SUMO1 conjugation
.
Proc Natl Acad Sci U S A
2007
;
104
:
6684
9
.

32

Stallwood
Y
,
Fisher
KD
,
Gallimore
PH
,
Mautner
V
.
Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients
.
Gene Ther
2000
;
7
:
637
43
.

33

Engler
H
,
Machemer
T
,
Philopena
J
et al. .
Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha
.
Virology
2004
;
328
:
52
61
.

34

Lion
T
.
Adenovirus infections in immunocompetent and immunocompromised patients
.
Clin Microbiol Rev
2014
;
27
:
441
62
.

35

Flomenberg
P
,
Babbitt
J
,
Drobyski
WR
et al. .
Increasing incidence of adenovirus disease in bone marrow transplant recipients
.
J Infect Dis
1994
;
169
:
775
81
.

36

Lion
T
,
Baumgartinger
R
,
Watzinger
F
et al. .
Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease
.
Blood
2003
;
102
:
1114
20
.

37

Walls
T
,
Shankar
AG
,
Shingadia
D
.
Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients
.
Lancet Infect Dis
2003
;
3
:
79
86
.

38

Feuchtinger
T
,
Lang
P
,
Handgretinger
R
.
Adenovirus infection after allogeneic stem cell transplantation
.
Leuk Lymphoma
2007
;
48
:
244
55
.

39

Ljungman
P
.
Treatment of adenovirus infections in the immunocompromised host
.
Eur J Clin Microbiol Infect Dis
2004
;
23
:
583
8
.

40

Ronan
BA
,
Agrwal
N
,
Carey
EJ
et al. .
Fulminant hepatitis due to human adenovirus
.
Infection
2014
;
42
:
105
11
.

41

Zarubaev
VV
,
Garshinina
AV
,
Kalinina
NA
et al. .
Activity of Ingavirin (6-[2-(1H-Imidazol-4-yl)ethylamino]-5-oxohexanoic Acid) Against Human Respiratory Viruses in in Vivo Experiments
.
Pharmaceuticals
2011
;
4
:
1518
34
.

42

Chen
Q
,
Khoury
M
,
Chen
J
.
Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice
.
Proc Natl Acad Sci U S A
2009
;
106
:
21783
8
.

43

Duncan
SJ
,
Gordon
FC
,
Gregory
DW
et al. .
Infection of mouse liver by human adenovirus type 5
.
J Gen Virol
1978
;
40
:
45
61
.

44

Paielli
DL
,
Wing
MS
,
Rogulski
KR
et al. .
Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse
.
Mol Ther
2000
;
1
:
263
74
.

45

Young
AM
,
Archibald
KM
,
Tookman
LA
et al. .
Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo
.
Mol Ther
2012
;
20
:
1676
88
.

46

Kosulin
K
,
Geiger
E
,
Vecsei
A
et al. .
Persistence and reactivation of human adenoviruses in the gastrointestinal tract
.
Clin Microbiol Infect
2016
;
22
:
381 e1
8
.

47

Araújo
AA
,
Yokosawa
JD
,
Durigon
EL
,
Ventura
AM
.
Polymerase chain reaction detection of adenovirus dna sequences in human lymphocytes
.
Braz J Microbiol
2001
;
32
:
153
7
.

48

Billerbeck
E
,
Horwitz
JA
,
Labitt
RN
et al. .
Characterization of human antiviral adaptive immune responses during hepatotropic virus infection in HLA-transgenic human immune system mice
.
J Immunol
2013
;
191
:
1753
64
.

49

Wherry
EJ
.
T cell exhaustion
.
Nat Immunol
2011
;
12
:
492
9
.

50

Ruibal
P
,
Oestereich
L
,
Ludtke
A
et al. .
Unique human immune signature of Ebola virus disease in Guinea
.
Nature
2016
;
533
:
100
4
.

Author notes

Presented in part: 3rd Meeting on Emerging Oncogenic Viruses, San Pietro in Bevagna, Manduria, Italy, 4–8 June 2014; 11th International Adenovirus Meeting, La Jolla, California, 16–20 July 2014; ICGEB DNA Tumor Virus Meeting, Trieste, Italy, 21–26 July 2015; International Workshop on Humanized Mice 5, Zurich, Switzerland, 28–30 January 2016; 12th International Adenovirus Meeting, Barsinghausen, Germany, 16–20 August 2016.

Supplementary data